This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Humanigen Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Humanigen te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

May 05

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Mar 31

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Feb 26

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Jan 29

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Jan 11

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Jan 04

Humanigen secures new U.S. patent for lenzilumab

Dec 28

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Dec 17

Humanigen EPS misses by $0.16

Nov 11

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Nov 06

Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Nov 03

Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 01

Dosing underway in lenzilumab late-stage study in COVID-19

Oct 30

Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19

Oct 29

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Humanigen onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:HGEN.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2023	2	-54	-64	-64	N/A
12/31/2022	3	-71	-77	-77	N/A
9/30/2022	3	-109	-94	-94	N/A
6/30/2022	4	-152	-125	-125	N/A
3/31/2022	4	-192	-168	-168	N/A
12/31/2021	4	-237	-184	-184	N/A
9/30/2021	3	-235	-175	-175	N/A
6/30/2021	2	-199	-151	-151	N/A
3/31/2021	1	-153	-105	-105	N/A
12/31/2020	0	-90	-70	-70	N/A
9/30/2020	N/A	-59	-47	-47	N/A
6/30/2020	N/A	-31	-24	-24	N/A
3/31/2020	N/A	-10	-4	-4	N/A
12/31/2019	N/A	-10	-4	-4	N/A
9/30/2019	N/A	-10	-5	-5	N/A
6/30/2019	N/A	-10	-5	-5	N/A
3/31/2019	N/A	-9	-5	-5	N/A
12/31/2018	N/A	-12	-6	-6	N/A
9/30/2018	N/A	-13	-7	-7	N/A
6/30/2018	N/A	-18	-10	-10	N/A
3/31/2018	N/A	-22	-12	-12	N/A
12/31/2017	N/A	-22	-14	-14	N/A
9/30/2017	N/A	-24	-15	-15	N/A
6/30/2017	N/A	-21	-20	-20	N/A
3/31/2017	N/A	-27	-23	-23	N/A
12/31/2016	N/A	-27	N/A	-21	N/A
9/30/2016	N/A	-35	N/A	-26	N/A
6/30/2016	N/A	-37	N/A	-23	N/A
3/31/2016	N/A	-31	N/A	-22	N/A
12/31/2015	N/A	-35	N/A	-29	N/A
9/30/2015	N/A	-32	N/A	-28	N/A
6/30/2015	N/A	-33	N/A	-30	N/A
3/31/2015	N/A	-37	N/A	-34	N/A
12/31/2014	N/A	-38	N/A	-36	N/A
9/30/2014	0	-39	N/A	-39	N/A
6/30/2014	0	-42	N/A	-39	N/A
3/31/2014	0	-44	N/A	-42	N/A
12/31/2013	0	-42	N/A	-39	N/A
9/30/2013	0	-43	N/A	-37	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van HGEN.Q boven de spaarquote ( 2.4% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van HGEN.Q naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van HGEN.Q naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van HGEN.Q naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van HGEN.Q naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van HGEN.Q naar verwachting over 3 jaar hoog zal zijn

This company is no longer active

Humanigen Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$4.75

Consensus revenue estimates increase by 34%

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Recent updates

Humanigen, Inc. Filed for Bankruptcy

Levi & Korsinsky, LLP and Pomerantz LLP Announce A Proposed Settlement for the in Re Humanigen, Inc. Securities Litigation

The Nasdaq Stock Market to Delist the Common Stock of Humanigen

Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer

Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index

Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index

Humanigen, Inc. Announces Board Changes

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.035 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.75

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Humanigen Receives Non-Compliance Letter from Nasdaq

Bernstein Liebhard LLP Announces Class Action Lawsuit Against Humanigen, Inc

Humanigen, Inc. Announces Executive Changes

Humanigen, Inc. Announces Resignation Adrian Kilcoyne as Chief Medical Officer, Effective September 28, 2022

Pomerantz LLP Announces the Filing of a Class Action Against Humanigen, Inc. and Certain of its Officers

Consensus revenue estimates increase by 34%

First half 2022 earnings released

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Price target decreased to US$8.70

Humanigen, Inc. Receives Preliminary Topline Data from NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B

Humanigen plunges 57% as trial for COVID-19 therapy fails

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Consensus revenue estimates increase by 19%

Humanigen, Inc., Annual General Meeting, Jun 09, 2022

Chairman & CEO recently bought US$94k worth of stock

Forecast to breakeven in 2023

Consensus revenue estimates increase by 12%

Forecast to breakeven in 2023

Humanigen Launches Managed Access Program for Lenzilumab

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

Humanigen, Inc. Announces Target Enrollment in Phase 2/3 Activ-5/Bet-B Trial of Lenzilumab for the Treatment of Covid-19 Has Been Achieved

Humanigen, Inc. Announces A Manuscript Detailing the Results of an Analysis of CRP Levels from the Live-Air Phase 3 Study

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

FDA Declines Humanigen’s Emergency Use Authorization Request for Lenzilumab in Hospitalized COVID-19 Patients

Price target decreased to US$28.33

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Chairman & CEO recently sold US$1.7m worth of stock

Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Humanigen Submits Application to FDA for Emergency Use Authorization for lenzilumab in Covid-19

Humanigen submits lenzilumab COVID-19 EUA application to FDA

Eversana Advances Commercialization Readiness as Humanigen Announces Publication of Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Newly Hospitalized Covid-19 Patients

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Price target increased to US$32.14

Humanigen, Inc., Annual General Meeting, Jun 17, 2021

Humanigen, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

Earnings beat expectations

Chief Accounting & Administrative Officer, Corporate Secretary and Treasurer has left the company

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

New 90-day high: US$23.83

Humanigen, Inc. Announces Executive Changes

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

Humanigen, Inc. Completes Enrollment in Phase 3 Study of Lenzilumab

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational Covid-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

Humanigen, Inc Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19

Humanigen, Inc. and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Humanigen, Inc. Announces Retirement of Robert G. Savage from the Board of Directors

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Humanigen secures new U.S. patent for lenzilumab